# An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

> **NCT01022112** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 383 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** TA-7284-Low
- **DRUG:** TA-7284-Low-middle
- **DRUG:** TA-7284-High-middle
- **DRUG:** TA-7284-High
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01022112
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022112, "An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01022112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*